PLAC1L inhibitors represent a class of chemical compounds designed to target and inhibit the activity of the PLAC1L protein, a specific member of the placenta-specific family of proteins. PLAC1L is encoded by a gene located on the X chromosome and is thought to play a role in various cellular processes related to placental and embryonic development. The inhibitors of PLAC1L are crafted with precision to interact with the active or binding sites of this protein, disrupting its function and the downstream signaling pathways it may influence. Structurally, PLAC1L inhibitors often contain specific chemical moieties that enable them to bind selectively to PLAC1L, preventing its normal biological interactions, thus halting its ability to contribute to specific cellular pathways. These inhibitors are usually small molecules with finely tuned physicochemical properties, such as optimized lipophilicity, solubility, and molecular weight, allowing for precise targeting and modulation of PLAC1L-related biological functions.
From a chemical standpoint, PLAC1L inhibitors undergo extensive development involving techniques like high-throughput screening, molecular docking studies, and structure-activity relationship (SAR) analyses. Such approaches allow chemists to identify lead compounds with the highest affinity for PLAC1L. Once promising leads are identified, they are subjected to optimization, where their chemical structures are adjusted to enhance their binding specificity, reduce off-target effects, and improve their overall stability. Common strategies in the development of PLAC1L inhibitors include the use of heterocyclic frameworks and aromatic rings, which facilitate strong interactions with the target protein. Additionally, the inhibitors are often designed to avoid rapid metabolic degradation, increasing their persistence within cellular environments. These efforts ensure that the inhibitors can reliably block PLAC1L function, allowing scientists to further explore the protein's role in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
May disrupt DNA methylation patterns, potentially leading to the silencing of PLAC1L gene transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Could enhance histone acetylation, resulting in the chromatin remodeling necessary to repress PLAC1L gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Might induce hyperacetylation of histones associated with the PLAC1L gene, leading to a condensed chromatin state and reduced transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Has the potential to repress PLAC1L expression by altering retinoid-responsive cellular pathways and transcription factor binding. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Could lead to a depletion of nucleotide pools, thereby hindering the synthesis of the PLAC1L mRNA transcript. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
May decrease PLAC1L expression by inhibiting mTOR signaling, which is often associated with the control of protein synthesis. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Possesses the potential to downregulate PLAC1L expression by interfering with specific signal transduction pathways linked to cell growth and survival. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
May attenuate PLAC1L mRNA levels by activating detoxification pathways that lead to the repression of certain oncogenes. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Could suppress the transcription of PLAC1L through attenuation of NF-κB signaling, which is implicated in the control of numerous genes. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Might inhibit the degradation of regulatory proteins that suppress PLAC1L gene transcription, resulting in decreased PLAC1L expression. | ||||||